Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis (NCT06850727)
A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the clinical efficacy and safety of OD-07656 in participants with moderately to severely active ulcerative colitis (UC). In addition, the study will evaluate the potential of OD-07656 to enhance the therapeutic benefit of vedolizumab when given after OD-07656.
Who can join: Review the eligibility criteria below.
Location: Sunshine Coast University — Birtinya
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (32 Sites)
Showing the first 25 of 32 sites.
- Sunshine Coast University — Birtinya,
- Eastern Health — Box Hill,
- Coastal Digestive Health — Maroochydore,
- Alfred Health — Melbourne,
- Fiona Stanley Hospital — Murdoch,
- Royal Melbourne Hospital — Parkville,
- Medical University of Graz — Graz,
- CHUM — Montreal,
- Montreal General Hospital/McGill University — Montreal,
- CHUM - Pavillon R — Polička,
- Jordan University Hospital — Amman,
- The Specialty Hospital (TSH) / Advanced Clinical Center — Amman,
- Irbid Specialty Hospital — Irbid,
- The Hospital of Lithuanian University of Health Sciences — Kaunas,
- IMSP Spitalul Clinic Republican Timofei Moneaga — Chisinau,
- PCRN Auckland — Auckland,
- PCRN Christchurch — Christchurch,
- PCRN Waikato — Hamilton,
- PCRN Tasman — Nelson,
- PCRN Wellington — Upper Hutt,
- Centrum Medyczne — Bydgoszcz,
- Centrum Medyczne LukaMed — Chojnice,
- Vita Longa Sp. z.o.o. — Katowice,
- Centrum Medyczne Medyk — Rzeszów,
- Endoskopia Sp. z.o.o — Sopot,
📞 Contact the Study Coordinator
Phone: (857) 393-6160
Email: clinicaltrials@odysseytx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ulcerative Colitis (UC)
- Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants — Miami, Florida
- A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) — Birmingham, Alabama
- A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis — Coronado, California
- A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) — Mobile, Alabama
- Using Breath Tests to Study Gut Sulfur Changes During Dietary Therapy — Kelowna, British Columbia
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis — Miami, Florida
Explore by condition: All Ulcerative Colitis (UC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.